Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the
efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of
patients with inoperable or metastatic bile duct adenocarcinoma